Disclosed is the use of a composition comprising nanoparticles that comprise rapamycin or a derivative thereof and a carrier protein (such as nab-rapamycin) in the manufacture of a medicament for treating cancer in an individual, wherein the medicament is formulated for administration at least once every two weeks, wherein the composition to be administered to the individual has an effective amount of rapamycin or the derivative thereof at about 54 mg to about 540 mg.
